AstraZeneca, AtheroGenics pipeline compound fails to meet trial goals
AstraZeneca and collaboration partner AtheroGenics said AGI-1067, an experimental drug in development for the treatment of atherosclerosis, fell short of ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.